BTG plc (BTG) Announces Earnings Results
BTG plc (LON:BTG) issued its quarterly earnings results on Tuesday. The company reported GBX 21 ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of GBX 21 ($0.28), Bloomberg Earnings reports. BTG plc had a net margin of 7.26% and a return on equity of 4.33%. The firm had revenue of GBX 3,413 billion during the quarter.
BTG plc (LON BTG) opened at GBX 705.50 ($9.28) on Thursday. BTG plc has a 1-year low of GBX 528.36 ($6.95) and a 1-year high of GBX 779 ($10.25).
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/btg-plc-btg-announces-earnings-results/1706595.html.
A number of analysts have weighed in on the stock. Deutsche Bank AG reissued a “buy” rating and issued a GBX 775 ($10.19) price target on shares of BTG plc in a report on Tuesday, November 7th. Peel Hunt reissued a “hold” rating and issued a GBX 680 ($8.94) price target on shares of BTG plc in a report on Tuesday. J P Morgan Chase & Co reissued a “neutral” rating on shares of BTG plc in a report on Friday, October 6th. Numis Securities Ltd reissued a “buy” rating and issued a GBX 900 ($11.84) price target on shares of BTG plc in a report on Wednesday, August 9th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a GBX 800 ($10.52) price target on shares of BTG plc in a report on Wednesday, August 30th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of GBX 779.13 ($10.25).
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with Analyst Ratings Network's FREE daily email newsletter.